Zobrazeno 1 - 10
of 53
pro vyhledávání: ''
Autor:
E De Cock, Guy Hechmati, T. Besse-Hammer, F Gatta, S. Tao, J.J. Body, V Fikkert, Marc Peeters, Jeroen Mebis, P. Kritikou
Publikováno v:
Value in Health. 18(7)
Autor:
Jinhyun Kim, Younhee Kim
Publikováno v:
Value in Health. 12:S78-S81
Objectives: This study aims to conduct an economic evaluation of oral deferasirox (DSX) compared with infusional deferoxamine (DFO) in patients with transfusional iron overload. Methods: Depending on the methods for measuring time-cost and convenienc
Publikováno v:
Value in Health. 20:A463
Publikováno v:
Value in Health. 18(3)
Figure 2. Effect of (A) Lorcaserin and (B) Placebo on Weight Loss at 1 Year in Patients With Baseline BMI ≥40 kg/m Figure 3. Effect of (A) Lorcaserin and (B) Placebo on Weight Loss at 1 Year in Patients With Baseline BMI 35–39.9 kg/m T-P 3139 Cos
Publikováno v:
Value in Health. 17(7)
Publikováno v:
Value in Health. 19:A151-A152
Autor:
L. Najun Dubos, L Renati
Publikováno v:
Value in Health. 18:A442-A443
Autor:
A.M. Gilligan, Curtis Waycaster
Publikováno v:
Value in Health. 17(3)
Publikováno v:
Value in Health. 16(7)
Publikováno v:
Value in Health. 16(7)
Objectives Warfarin-treated patients with poor international normalized ratio (INR) control, measured with time in therapeutic range (TTR) or the standard deviation of transformed INR (SDTINR), have an increased risk for clinical events. To what exte